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           Regulatory T (T reg) cells have a major role in 
tumor-related immune suppression (  1  ). T reg 
cells accumulate in both human and mouse tu-
mors, as well as in secondary lymphoid organs 
being recruited (  2  ) and expanded either by the 
proliferation of preexisting T reg cells (  3  ) or the 
conversion of CD25        T cells (  4, 5  ). T reg cells 
suppress a variety of immune cells, such as CD4 
and CD8 T lymphocytes (  6  ), NK cells (  7  ), and 
B lymphocytes (  8  ). Moreover, direct inhibition 
of DC function has been demonstrated in vitro 
(  9, 10  ), whereas in vivo evidence is from intra-
vital microscopy applied to mouse models of 
autoimmune diseases (  11, 12  ). Tumor-associated 
T reg cells likely contribute to the suppressive 
milieu in which DCs cannot maturate and acti-
vate properly (  13, 14  ). 
  OX40 is a co-stimulatory molecule be-
longing to the TNF receptor family. It is tran-
siently expressed on CD4 lymphocytes upon 
antigen stimulation and is conducive to up-
regulation of the antiapoptotic proteins Bcl-xL 
and Bcl-2 (  15  ). OX40 regulates the diff  erentia-
tion (  16  ), primary clonal expansion, and mem-
ory development (  17  ) of CD4 lymphocytes 
and activation of CD8 cells (  18  ). Triggering 
OX40 in vivo has been shown to prevent tol-
erance induction and to revert lymphocyte hy-
poresponsiveness in experimental tolerogenic 
systems (  19, 20  ). OX40 is largely involved in 
the pathogenesis of autoimmune disease; the 
blockade of the OX40  –  OX40L axis ameliorates 
autoimmune symptoms (  21  ). 
  Although inhibition of OX40 signaling is 
thought to be benefi  cial to treat autoimmunity, its 
triggering improves immune response to cancer. 
Indeed, systemic administration of OX40L  –  Ig 
fusion protein or of the agonist mAb OX86 
induces the rejection of diff  erent types of mouse 
transplantable tumors (  22, 23  ). OX40 trigger-
ing can synergize with other immunostimula-
tory molecules. CT26 colon carcinoma cells 
transduced to stably express both OX40L and 
GM-CSF, thus combining GM-CSF  –  mediated 
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  Regulatory T (T reg) cells are the major obstacle to cancer immunotherapy, and their deple-
tion promptly induces conversion of peripheral precursors into T reg cells. We show that T 
reg cells can be functionally inactivated by OX40 triggering. In tumors, the vast majority of 
CD4  +   T cells are Foxp3  +   and OX40  bright  . However, intratumor injection of the agonist anti-
OX40 monoclonal antibody (mAb) OX86, but not anti-CD25 mAb, induces tumor rejection 
in 80% of mice, an effect that is abrogated by CD8 depletion. Upon intratumor OX40 
triggering, increased numbers of infi  ltrating dendritic cells (DCs) migrate to draining lymph 
nodes and generate a new wave of tumor-specifi  c cytotoxic T lymphocytes, as detected by 
tetramer and CD44 staining of node CD8  +   T lymphocytes. Tumor-bearing Rag1-knockout 
(KO) mice reconstituted with OX40-defi  cient T reg cells and wild-type (WT) effector T 
cells, or the reciprocal combination, showed that both T reg and effector T cells must be 
triggered via OX40 for the tumor to be rejected. Accordingly, WT but not OX40-KO mice 
receiving intratumor coinjection of OX86 and ovalbumin protein were able to revert tu-
mor-induced tolerization of adoptively transferred OX40-competent OTII T lymphocytes. 
In conclusion, OX40-mediated inactivation of T reg cell function unleashes nearby DCs, allowing 
them to induce an adaptive immune response. In addition, the known OX40-dependent 
delivery of fi  tness signals to activated T cells is boosted by concurrent T reg cell inhibition. 
OX40 triggering thus has multiple effects that converge to mediate tumor rejection. 826 OX40 ANTITUMOR EFFECTS PASS THROUGH T REG BLOCKADE | Piconese et al.
bility to revert T reg cell suppression ( 27, 30 ) and to co-stimulate 
eff  ector T cell responses (  31  ) with OX40. GITR stimulation 
eradicates incipient tumors (  32, 33  ) and enhances immune re-
sponse to antitumor vaccination (  34  ) by boosting CD8 T cells, 
apparently in the absence of any eff  ect on T reg cell function, 
while expanding their number (  33  ). Mild autoimmunity has 
been associated with GITR triggering (  34  ), which can be 
avoided by confi  ning the treatment to the tumor mass (  32  ). 
  Because T reg cells constitute the predominant CD4 sub-
population in tumor-bearing hosts, T reg cell manipulation is 
a necessary step toward immunotherapy. Among possible 
strategies, CD25 depletion should be excluded as not dis-
criminating between T reg cells and activated eff  ector T cells. 
On the other hand, CD4 intratumor depletion, although ef-
fective in treating growing tumors as it spares CD8-activated 
eff  ector cells, shows limited application to late-stage lesions 
(  35  ). Moreover, both approaches produce a local T reg cell 
depletion that rapidly drives recruitment of both preexisting 
and newly converted T reg cells (  4  ). Our study shows that 
the singular administration of agonist anti-OX40 mAb pro-
tects naive mice from subsequent tumor challenge and eradi-
cates already established tumors when injected within the 
lesions. Tumor-infi  ltrating T reg cell inhibition generate a 
favorable context that allows DCs to traffi   c toward the drain-
ing lymph node and to prime a new wave of tumor-specifi  c 
CD8 lymphocytes responsible for tumor rejection. In addi-
tion, agonistic mAb boosts OX40 on activated T cells, which 
also benefi  t from concurrent T reg cell inactivation. There-
fore, OX40 triggering, by suppressing without renewing the 
T reg cell pool, emerges as a promising component of future 
cancer immunotherapy. 
    RESULTS   
  OX40-triggering mAb protects from tumor challenge 
  Several studies have demonstrated that T reg cell depletion, 
by means of anti-CD25 mAb, before tumor injection leads to 
the rejection of immunogenic tumors (  36, 37  ). We tested 
whether the functional inhibition of naturally arising T reg 
cells by OX40 triggering is as eff  ective as T reg cell depletion. 
Naive BALB/c mice were injected i.p. with 1 mg anti-OX40 
(OX86), anti-CD25 (PC61) mAb, or isotype-matched con-
trol rat IgG 7 d before the s.c. inoculation of the syngeneic 
colon carcinoma cell line CT26. All mock-treated animals 
died of tumor within 2 wk, whereas PC61-treated mice de-
veloped tumor that was rejected by 25% of them. In sharp 
contrast, 70% of OX86-treated mice were completely pro-
tected from tumor challenge (  Fig. 1  ).   We analyzed the num-
ber and distribution of T reg cells at the time of tumor 
injection. Anti-OX40 mAb did not change T reg cell num-
bers in the spleen or lymph nodes, whereas anti-CD25 re-
markably reduced their numbers in every compartment 
analyzed (unpublished data). Ex vivo  –  restimulated spleno-
cytes, recovered from mice rejecting tumors upon either 
treatment, showed in vitro cytolytic activity against tumor 
cells and syngeneic blasts pulsed with the MHC class I  – 
restricted tumor-associated immunodominant gp70 peptide 
DC recruitment and an OX40L-induced T cell boost, are more 
immunogenic than single OX40L- or GM-CSF  –  transduced 
cells (  24  ). The combination of agonist 4-1BB and OX40 an-
tibodies with intratumor adenoviral delivery of IL-12 is more 
eff  ective than all single agents in treating hepatic colon metas-
tases (  25  ). OX40 engagement on CD8 lymphocytes has been 
successfully associated with GM-CSF  –  producing cell vaccina-
tion in treating spontaneous mammary tumors arising in FVB 
  MMTV-neu   transgenic mice (  26  ). 
  Emerging evidence attributes a key role in T reg cell biol-
ogy to OX40. OX40 is constitutively expressed by mouse T 
reg cells both in the naive state (  27, 28  ) and in the presence of 
tumors (  4  ). T reg cells from OX40-defi  cient mice are less 
numerous at young ages and less suppressive ex vivo than 
their OX40-suffi   cient counterparts (  28  ). Triggering OX40 
reverts the suppression exerted by T reg cells over CD4 cells 
in vitro (  27, 28  ), mainly by directly impairing T reg cell func-
tion rather than by enabling responder cells to resist T reg cell 
suppression (  27  ). Moreover, T reg cells preincubated with the 
agonist mAb OX86 lose the ability to suppress eff  ector T cells 
in an in vivo mouse model of graft-versus-host disease (  27  ). 
  Another member of the TNF receptor family, the gluco-
corticoid-induced TNF receptor (GITR) (  29  ), shares the capa-
    Figure 1.         OX40 triggering protects from tumor challenge.   5   ×   10 4  
CT26 colon carcinoma cells were injected s.c. into the right fl  ank of BALB/c 
mice 7 d after the systemic administration of 1 mg anti-OX40 mAb OX86 
(A) or anti-CD25 mAb PC61 (B). As mock treatment, rat IgG was injected. 
Tumor growth was monitored twice per week. The percentages of tumor-
free mice are given at the indicated time points. Six mice were included in 
each experimental group. Results are from one representative out of three 
independent experiments.     JEM VOL. 205, April 14, 2008 
ARTICLE
827
  Fig. 2 D   shows the eff  ective reduction of natural T reg cell 
numbers at the time of anti-OX40 administration that per-
sisted until the time of tumor challenge. From these data, we 
concluded that OX40 triggering protects from tumor chal-
lenge mainly by neutralizing the function of naturally arising 
T reg cells. 
  However, this does not exclude that the persistence of 
antibodies in circulation makes possible their eff  ect on primed 
T cells that gain OX40 and CD25 on the surface. Thus, per-
sisting anti-OX40 mAb could co-stimulate eff  ector T cells 
and further improve the antitumor response. Conversely, 
persistent anti-CD25 could result in eff  ector T cell depletion, 
a process that may counterbalance the favorable consequences 
of T reg cell depletion. Therefore, these experiments strongly 
indicate that the superior antitumor eff  ect of OX86 over 
PC61 is expected to become more evident in a therapeutic 
setting in which concomitant immunity, although suppressed, 
should be present. 
AH1 (unpublished data). Mice rejecting CT26 cells after ei-
ther treatment were resistant to a subsequent challenge with 
the same cell line but not with tumors lacking the expression 
of gp70 protein (unpublished data). These results indicate that 
triggering OX40 in vivo before tumor challenge allows the 
development of a specifi  c and long-lasting antitumor immune 
response superior to that induced by T reg cell depletion. 
  OX40-mediated protection depends on T reg cell inhibition 
  At the naive stage, the only cells constitutively expressing 
OX40 are the Foxp3  +   CD25  +   T reg cells (unpublished data) 
(  27  ); therefore, they are the only possible target of anti-OX40 
mAb. To test this hypothesis, we depleted naturally arising 
T reg cells by injecting anti-CD25 mAb 7 d before OX86 
treatment that was 7 d before tumor challenge. As for the 
previously described experiments, anti-OX40 alone was more 
eff  ective than anti-CD25, but the eff  ect was lost in mice de-
pleted of natural T reg cells before OX86 treatment (  Fig. 2  ).   
    Figure 2.         OX40-induced protection is through T reg cell inhibition.   Effect of OX86 mAb in the absence of T reg cells. 1 mg anti-CD25 mAb or anti-
OX40 mAb was administered i.p. to BALB/c naive mice before injection of 5   ×   10  4   CT26 cells. As mock treatment, rat IgG was injected. OX86 mAb was 
given to mice pretreated or not with PC61 mAb, and rat IgG was given as mock treatment. All mice were challenged with 5   ×   10  4   CT26 tumor cells at day 0. 
(A) PC61 was injected 14 d before tumor challenge. (B) 7 d later, half of the PC61-treated mice received OX86 or rat IgG injection. (C) A mice cohort 
received OX86 only 7 d before tumor challenge. Tumor growth was monitored twice per week. One representative out of two independent experiments is 
shown. (D) Effective T reg cell depletion was monitored by Foxp3 staining in lymph nodes 7 and 14 d after PC61 or OX86 injection. Each symbol corre-
sponds to a single lymph node from each mouse analyzed among the experimental groups. The solid line represents the median value. Representative 
plots of CD4 versus Foxp3 expression (percentages) are shown for the day 7 observation.     828 OX40 ANTITUMOR EFFECTS PASS THROUGH T REG BLOCKADE | Piconese et al.
  Tumor-infi  ltrating T reg cells express functional OX40 
  We tested the eff  ects of OX40 triggering in the therapeutic set-
ting and, because of the possible induction of generalized auto-
immunity in the event of systemic T reg cell inhibition (  32  ), we 
decided for intratumor injection of agonistic mAb. To charac-
terize the context in which OX86 mAb should operate, we 
evaluated the expression of CD25, Foxp3, and OX40 on CD4  +   
T cells purifi  ed from CT26 tumors of     3  –  4 mm in size, in 
comparison to spleens from tumor-free mice as a baseline. The 
majority of CD4  +   tumor-infi  ltrating lymphocytes (TILs) were 
CD25  +   and Foxp3  +   (  Fig. 3 A  ), and their expression of OX40 
was much brighter than in control splenocytes (  Fig. 3 B  ).   
  To test whether OX40 conveys the same inhibitor signal 
to tumor-infi  ltrating T reg cells, in comparison to those col-
lected from the spleens of tumor-free mice, T reg cells were 
incubated for 2 h with OX86 mAb or with control rat IgG 
before being added to polyclonally activated and CFSE-la-
beled CD4  +   CD25        T cells in a standard in vitro suppression 
assay. Both tumor- and control spleen  –  derived T reg cells 
suppress the proliferation of responder cells in a dose-depen-
dent manner, but not if preincubated with OX86 (  Fig. 3 C  ). 
More compelling, T reg cells freshly isolated from OX86-
treated tumors in vivo lost their suppression when tested 
ex vivo (  Fig. 3 C  ). These data confi  rm that CT26-infi  ltrating 
T reg cells express OX40 and are effi   ciently inhibited for the 
suppressive function by OX40 triggering. 
  Intratumor OX40 triggering leads to complete 
tumor rejection 
  Tumor-infi  ltrating T reg cells play a major role in establishing 
and maintaining the state of immune suppression within the 
tumor microenvironment. Their inhibition could rescue the 
endogenous immune response from paralysis, thus leading to 
the rejection of tumors endowed with some immunogenic-
ity. To test this hypothesis, OX86 was injected within the 
tumor mass when CT26 cells reached     3  –  4 mm in size. Two 
single injections of 50   μ  g of mAb were performed within a 
2-d interval. As controls, anti-CD25 mAb (PC61) and anti-
CD4 (GK1.5)  –  depleting mAb or rat IgG were used at the 
same dose and schedule. Although all mock and PC61-treated 
animals were killed around day 20 because of excessive tumor 
burden (  Fig. 4, A and C  ), GK1.5-injected mice showed de-
layed tumor progression, and in 3 out of 10 mice a slow but 
progressive tumor rejection (  Fig. 4 D  ).   In this setting, both 
PC61 and GK1.5 deplete the CD4  +   T reg cell population, 
but only GK1.5 spares CD8  +   eff  ector T lymphocytes.      Figure 3.         Tumor-infi  ltrating T reg cells express functional OX40.   
(A) TILs were purifi  ed from a pool of CT26 tumor nodules, and the CD4  +   cell 
population was analyzed by fl  ow cytometry (percentages are shown). As 
controls, CD4  +   T cells were purifi  ed from the spleens of tumor-free mice 
(STF). (top) On gated CD4  +   T cells, the expression of Foxp3 versus CD25 was 
evaluated. (bottom) Among CD4  +   CD25 +   T cells, Foxp3 versus OX40 ex-
pression is shown. (B) OX40 expression was evaluated on gated CD4  +   Foxp3 +  
T cells from TILs of tumor-bearing mice. As controls, isotype staining on 
Foxp3  +   TILs and OX40 staining on Foxp3  +   CD4 +   splenocytes from tumor-free 
mice are shown. (C) CD4  +   CD25       T cells (Teff), obtained from the spleens of 
tumor-free mice, were CFSE labeled and seeded either alone or combined at 
1:1, 1:2, or 1:4 ratios with unlabeled CD4  +   T cells purifi  ed from TILs (T reg TIL) 
 
of tumor-bearing mice, either untreated or 6 h after intratumor OX86 injec-
tion (anti-OX40 in vivo). No major differences in the composition of tumor-
infi  ltrating CD4  +   T cells or in Foxp3 expression were evident 6 h after 
treatment. As controls, CD4  +   CD25 +   T cells from spleens of tumor-free mice 
were used (T reg STF). T reg cells were either pretreated with anti-OX40 mAb 
in vitro or with rat IgG as mock control. After 72 h, effector T cells were 
tested for CFSE dilution as a marker of proliferation. Representative plots of 
one out of three independent experiments are shown and indicate percent-
ages of proliferating (CFSE  low ) versus resting (CFSE  high ) effector T cells.    JEM VOL. 205, April 14, 2008 
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  Strikingly, OX86 induced complete tumor rejection in 
80% of treated mice and markedly reduced the growth of 
nonrejected tumors (  Fig. 4 B  ). Mice that successfully rejected 
the primary tumor were protected against a subsequent tu-
mor challenge (unpublished data), and their splenocytes dis-
played cytotoxic activity against tumor antigens upon ex vivo 
restimulation (unpublished data). Larger tumors (5  –  6 mm in 
diameter) were also rejected in six out of nine mice by anti-
OX40 treatment (unpublished data). 
  The described therapeutic eff  ect of agonistic anti-OX40 
mAb was not restricted to the CT26 colon carcinoma. TSA 
and N2C mammary tumors of BALB/c mice, as well as 
MCA203 fi  brosarcoma of C57BL/6 mice, were also rejected 
in     70% of treated mice (  Fig. 5  ).   
  Adaptive immune response is required for OX40-induced 
tumor rejection 
  To dissect the immune mechanisms contributing to tumor 
rejection, mice were systemically injected with anti-CD8 de-
pleting mAb (2.43) the day before and the same day of OX86 
intratumor administration. In CD8-depleted mice, OX86 
lost eff  ect and tumors grew without diff  erence in comparison 
to OX86-untreated tumors (  Fig. 6  ).   
  These results raised the question of whether T reg cell in-
hibition unleashes the activity of preexisting CTLs or favors 
the generation of new CTLs. Tumor-infi  ltrating T reg cells 
could hamper tumor-draining node communication, most 
likely by inhibiting tumor-infi  ltrating DC (TIDC) function. 
To test whether DC migration is necessary for OX40-induced 
tumor regression, we used CCR7-KO mice, whose DCs can-
not enter lymph nodes in response to the chemokine CCL21 
and remain in peripheral tissues (  38  ). Tumors grown in WT 
or CCR7-KO mice were treated with OX86 or with rat IgG 
as control. 90% of WT but no CCR7-KO mice rejected 
their tumors upon OX86 treatment (  Fig. 7 A  ).   This result 
suggests that DC migration to draining lymph nodes is re-
quired for OX40-mediated tumor rejection, and that newly 
primed eff  ector T cells are necessary to complete tumor re-
jection in this experimental setting. 
  It can be argued that T cells, besides TIDCs, have impaired 
migration to lymph nodes in CCR7-KO mice and that tumor 
rejection should not be possible at any rate because of an intrinsic 
defect of T cells rather than DCs. However, this possibility is dis-
puted by the fi  nding of numerous CD25  +   Foxp3        T cells within 
the tumors from CCR7-KO mice, perhaps derived from extra-
nodal priming (  Fig. 7 B  ). Although indirect, these data suggest 
the hypothesis that T reg cell functional inhibition should restore 
DC function toward the production of new eff  ector T cells. 
  Rescue of DC migration results in the priming 
of tumor-specifi  c effectors at draining lymph nodes 
  To verify the above hypothesis, we tested whether tumor 
treatment with OX86 releases TIDCs from suppression and 
recovers their migration properties. Almost all of the CT26-
infi  ltrating DCs belonged to the myeloid subset, and their 
surface expression of MHC class II and of co-stimulatory 
molecules (CD40, CD80, and CD86), which is typically 
low/intermediate in immature DCs, was not aff  ected 6 or 24 h 
after OX86 administration (unpublished data). To test whether 
TIDCs showed increased migratory capacity, we coinjected 
green fl  uorescent microbeads together with the OX86 mAb. 
Beads cannot reach the lymph node unless transported by 
DCs as engulfed particles. After 24 h, draining lymph nodes 
    Figure 4.         Intratumor OX40 triggering induces tumor rejection.   
5   ×   10 4   CT26 cells were injected s.c. in the right fl  ank of BALB/c mice. When 
tumors reached 3  –  4 mm in size, they received intratumor injection of 100   μ  g 
of purifi  ed rat IgG (A), anti-OX40 (B), anti-CD25 (C), or anti-CD4 mAb (D). 
Tumor volume was calculated as longest diameter   ×   (shortest diameter)  2  
(in cubic millimeters). Lines represent the tumor growth kinetics in each single 
mouse. The number of tumor-free mice out of the number of treated mice is 
indicated. One representative of three independent experiments is shown.    830 OX40 ANTITUMOR EFFECTS PASS THROUGH T REG BLOCKADE | Piconese et al.
are recently activated rather than memory T cells returned 
from the tumor site. This confi  rms that the priming of new 
CTLs actually occurs at the draining lymph node as a conse-
quence of TIDC evasion from T reg cell suppression. 
  T reg cell inhibition and effector T cell co-stimulation are 
both required in OX86-induced tumor rejection 
  In addition to T reg cells, incipient tumors are infi  ltrated 
by some Foxp3        OX40  +   activated eff  ector T cells that are 
readily responsive to the agonistic OX40 mAb. Thus, tumor 
rejection might result from the dual triggering of both T reg 
cells and eff  ector T cells. To test this possibility against a 
distinct, predominant role of T reg cell inhibition versus eff  ec-
tor T cell co-stimulation, we generated mice in which T reg 
cells or eff  ector T cells were alternatively OX40 null. To 
this end, C57BL/6 Rag1-KO mice were reconstituted with 
CD4  +   CD25        (eff  ector T cells) from WT (CD45.1) mice and 
CD4  +   CD25  +   (T reg cells) from OX40-KO (CD45.2) mice, 
or vice versa, in the presence of CD8 WT T cells. Eff  ector 
were analyzed for the presence of CD11c  +   cells emitting 
green fl  uorescence because of the engulfed microbeads. As a 
control, anti-CD25 mAb or rat IgG were coinjected with 
fl  uorescent microbeads. The absolute number of green DCs 
within draining lymph nodes was signifi  cantly higher in OX86- 
versus control-treated mice (  Fig. 8 A  ).   This result confi  rms 
that tumor-infi  ltrating T reg cells inhibit nearby DCs and 
that T reg cell functional inhibition restores their activities. 
  The rescue of TIDC function is clearly part of the mech-
anisms leading to tumor rejection upon OX86 treatment. To 
confi  rm such a role, we evaluated the percentage of tetramer-
specifi  c CD8  +   T cells recognizing AH1, the L  d  -restricted 
gp70-env immunodominant peptide expressed by CT26 car-
cinoma. 5 d after treatment, the fraction of CD8  +   T cells spe-
cifi  c for AH1 peptide signifi  cantly increased in the draining 
lymph node of OX86 versus control-treated tumors (  Fig. 8 B  ). 
Moreover, the CT26-specifi   c CTLs did not express the 
memory marker CD44 (  Fig. 8 B  , insets) but instead the early 
activation marker CD69 (not depicted), suggesting that they 
    Figure 5.         OX86 intratumor injection eradicates tumors of different hystotypes.   N2C and TSA BALB/c mammary carcinomas, and MCA203 
C57BL/6 fi  brosarcoma of 3  –  4 mm in size received intratumor injection of 100   μ  g of purifi  ed rat IgG (left) or anti-OX40 (right). Tumor volume was calcu-
lated as longest diameter   ×   (shortest diameter)  2   (in cubic millimeters). Lines represent the tumor growth kinetics in each single mouse. The number of 
tumor-free mice out of the total number of treated mice is indicated. One representative of two independent experiments is shown.   JEM VOL. 205, April 14, 2008 
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T reg cells. Accumulation of suppressive lymphocytes results 
in immune paralysis, and inactivation of T reg cell suppres-
sion is a major goal for cancer immunotherapy. Indeed, the 
sole disruption of cell-intrinsic recessive tolerance in tumor 
bearers may not produce therapeutic eff  ects unless the T reg 
cell  –  induced dominant tolerance is eff  ectively and stably bro-
ken. In this paper, we show that T reg cell functional inhibi-
tion, by means of OX40 triggering, protects from subsequent 
tumor challenge and induces a complete rejection of already 
established nodules. We uncover the prominent mechanism 
allowing the activation of new tumor-specifi  c eff  ectors as a 
consequence of restored TIDC function by T reg cell inhibi-
tion. Eff  ector T cells can then be boosted by an agonistic OX40 
mAb, thus concurring with tumor rejection. 
  In naive mice, naturally arising T reg cells constitutively 
express OX40 and are virtually the only possible targets of 
T and T reg cells were mixed at the physiological 10:1 ratio to 
avoid the conversion of one subpopulation into the other (  39  ). 
Using the CD45 marker, we verifi  ed that CD4  +   CD25  +   Foxp3        
eff  ectors were derived through activation of naive CD4  +   
CD25        T cells, and that CD4  +   CD25  +   Foxp3  +   cells were from 
the expansion of CD4  +   CD25  +   donor T reg cells. 4 wk after 
reconstitution, mice were injected s.c. with 5   ×   10  5   cells of 
syngenic MCA203 fi  brosarcoma. When the tumor size reached 
3  –  4 mm, mice were treated with intratumor injection of OX86 
or control mAb.   Fig. 9   shows that control mice receiving both 
T reg and eff  ector T cells from WT donors rejected the tumor 
in response to OX86 treatment.   Conversely, mice reconsti-
tuted with either T reg or eff  ector T cells from OX40-KO 
donors showed tumor progression despite anti-OX40 treatment. 
In addition, mice receiving OX40-KO CD4 T cells (both ef-
fector T and T reg cells) and OX40-competent CD8 T cells 
did not reject tumor in response to OX86. The data clearly 
show that tumor rejection can result from the action of a single 
agent, the OX86 mAb, capable of double activity: inhibition 
of T reg cell function and boosting of eff  ector T cells. 
  OX40 triggering renders the tumor microenvironment 
permissive to immunity against an exogenous antigen 
  The above activities could also be improved by the newly de-
scribed eff  ect of OX40 triggering in preventing the conversion 
of T cells into T reg cells (  40, 41  ), an event that is exacerbated 
in tumor bearers (  4  ). To test this event in the tumor context, 
we transferred clonotypic CD4  +   CD25        OTII lymphocytes 
into either OX40-KO or WT mice already bearing MCA203 
fi  brosarcoma. Tumors of 3  –  4 mm were injected with 10   μ  g of 
OVA protein with or without OX86. 2 d later, draining lymph 
nodes were collected and OX40 expression by donor OTII 
cells was interpreted as a function of their activation, which, 
indeed, occurred without diff  erence between mice treated or 
not with OX86 and without diff  erence to tumor-free OTII-
recipient mice injected s.c. with OVA protein. Although all 
donor OTII cells were equally expressing OX40 and, there-
fore, potentially responsive to OX86 mAb, their gaining of 
Foxp3 in tumor bearers was inhibited by OX86 only if recipi-
ent mice were OX40 suffi   cient (  Fig. 10  ).   In OX40-KO recip-
ients, unimpaired conversion of OTII lymphocytes into T reg 
cells despite OX86 treatment indicates that tumor-infi  ltrating 
OX40  +  , rather than donor, T cells, are the prime targets of 
intratumoral-injected mAb. Because the absolute counts of 
Foxp3        clonotypic cells remain constant in all experimental 
groups, we exclude that preferential expansion of eff  ector cells 
might overestimate actual conversion rates (unpublished data). 
Also in TILs, OX86 reduces the conversion rate of clonotypic 
T cells in WT but not in OX40-KO recipients (unpublished 
data). These results further support the notion of OX40-medi-
ated local changes that turn the tumor milieu from suppressive 
into permissive to immune activation. 
    DISCUSSION   
  Growing tumors induce the expansion of natural T reg cells 
and the conversion of naive T cells into de novo  –  derived 
    Figure 6.         CD8  +   T cells are required for OX86-mediated rejection.  
(A) Mice bearing CT26 tumors of 3  –  4 mm in diameter were depleted of 
CD8  +   T cells immediately before receiving an intratumor injection of 100   μ  g 
of purifi  ed anti-OX40 mAb. As controls, mice received either anti-OX40 
alone (B) or anti-CD8 (C) mAb. Lines represent the tumor growth kinetics 
in each single mouse within the different experimental groups. The num-
ber of tumor-free mice out the total number of treated mice is indicated. 
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of an optimal immune response leading to the clearance of 
tumor cells depending on their immunogenicity. Although 
most of the eff  ects initiated by OX40 triggering are caused by 
T reg cell inactivation, we cannot exclude that the persistent 
presence of the agonistic mAb will boost eff  ector T cells as 
soon as they gain OX40 as part of their activation process. 
This OX40-mediated double eff  ect becomes more evident 
and testable when agonistic mAb is used in the therapeutic 
setting (see the following Discussion). 
  Anti-CD25 depleting mAb is much less effi   cient  than 
anti-OX40 in tumor prevention. Depletion of CD25  +   T cells, 
anti-OX40 mAb. In a setting of tumor prevention, the effi   -
cacy of anti-OX40 treatment is lost in mice previously de-
pleted of CD25  +   T cells. These data demonstrate that the in 
vivo inhibition of natural T reg cells allows the development 
of both innate and adaptive immune responses, whose medi-
ators were suppressed by T reg cells. The restored immunity 
includes DC reactivation and induction of tumor-specifi  c 
CTLs. Accordingly, mice rejecting the tumor because of 
T reg cell inhibition established immunological memory 
and cytotoxic activity that was detected in their splenocytes. 
At any rate, T reg cell inactivation permits the development 
    Figure 7.         OX86-induced tumor rejection is lost in CCR7-KO mice.   Effect of OX86 treatment in CCR7-KO mice. (A) 5   ×   10  4   CT26 cells were injected 
s.c. into the right fl  ank of WT (top) or CCR7-KO (bottom) mice. Tumors grew without difference between the two groups. At 3  –  4 mm in size, mice received 
intratumor injection of anti-OX40 mAb or rat IgG as control. Each line represents individual tumors. The number of tumor-free out the total number of 
treated mice is reported. The pooled data of three independent experiments are shown. (B) T cell infi  ltration in tumors from CCR7-KO mice. CD4  +   T cells 
were purifi  ed from a pool of CT26 tumors grown in CCR7-KO mice (TILs). As controls, splenocytes of tumor-free CCR7-KO mice were analyzed (STF). 
(top) On gated CD4  +   T cells, the percentage of CD25  +   versus  Foxp3 +   T cells was evaluated by fl  ow cytometry. (bottom) OX40 and Foxp3 expression were ana-
lyzed in the gated CD4  +   CD25 +   population. Both Foxp3  +   and  Foxp3       subsets were mostly OX40  +  , similarly to WT mice (  Fig. 3A  ). However, in contrast to WT 
mice, TILs from CCR7-KO mice contain a higher percentage of OX40  +   Foxp3       T cells, representing activated effector T cells.     JEM VOL. 205, April 14, 2008 
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from tumor challenge. Another possible explanation is the 
persistent circulation of anti-CD25 that eliminates the newly 
generated eff  ector T cells, which gain the CD25 at priming 
checked by means of Foxp3 staining, is incomplete, a fi  nding 
also reported by others (  42  –  44  ). The presence of few residual 
T reg cells may explain its low effi   cacy in protecting mice 
    Figure 8.         T reg cell inhibition by OX40 triggering allows TIDC maturation and priming of new CTLs.   (A) Rescue of DC migration after T reg cell in-
hibition. FITC-conjugated latex particles (2   ×   10  7   beads) of 1   μ  m in diameter were coinjected with anti-OX40, anti-CD25, or rat IgG (mock) within tumors of 
3  –  4 mm in diameter. After 24 h, axillary and inguinal draining lymph nodes were collected and treated with collagenase D, and the obtained cell suspensions were 
stained for CD11c. The number of CD11c  +   cells showing green fl  uorescence because of microbead engulfment was evaluated by fl  ow cytometry. Each symbol 
corresponds to a single draining lymph node; the solid line represents the median value. Results are a pooled representation of three independent experiments. 
*, P   <   0.05. (B) Induction of tumor-specifi  c CD8  +   T lymphocytes. (top) Tumor-bearing mice received intratumor injection of anti-CD25, anti-OX40, or rat IgG (mock). 
5 d after treatment, axillary and inguinal draining lymph nodes were collected and stained for fl  ow cytometry. On gated CD8  +   T cells, the percentage of tumor-
specifi  c clones was evaluated by staining with H2L  d   tetramers recognizing the SPSYVYHQF peptide of the gp70-env tumor-associated antigen. As a background 
staining, H2L  d   tetramers specifi  c for the unrelated peptide TPHPARIGL (  E. coli      -galactosidase 876  –  884) were used. Percentages of tumor-specifi  c CD8  +   T  cells 
were calculated by subtracting the background (    -galactosidase) from the specifi  c (gp70-env) staining. OX86-treated mice showed the highest percentage of 
tumor-specifi  c CD8  +   T cells in the draining lymph nodes. Each symbol represents the draining lymph node of randomly chosen mice from two independent ex-
periments. The solid line represents the median value. *, P   <   0.05. (bottom) Representative histograms of tetramer-stained cells gated on CD8  +   T cells are shown 
(indicated as percentages). Gp70-H2L  d   tetramer staining (continuous line) was overlaid with    -galactosidase – H2L d   control tetramer staining (shaded line). The 
subtracted value is indicated for each sample. (insets) Surface expression of the T cell memory marker CD44 on gp70-H2L  d   tetramer – positive  CD8 +   T  cells.   834 OX40 ANTITUMOR EFFECTS PASS THROUGH T REG BLOCKADE | Piconese et al.
naive precursors into de novo  –  induced T reg cells, as we and 
others have recently demonstrated ( 4, 47 ). In our tumor model, 
nodules of 3  –  4 mm in size are already associated with a sig-
nifi  cant accumulation of T reg cells in draining lymph nodes, 
in spleens, and, more importantly, in the tumor infi  ltrate, 
which is indicative of an active tumor immune escape. T reg 
cell inhibition by intratumor injection of agonistic OX40 
mAb induces tumor regression in 80% of treated mice, being 
able to actively revert the previously established state of dom-
inant immune tolerance. Therefore, although natural T reg 
cells regulate the elimination phase, tumor-associated T reg 
cells suppress the immune system during the escape phase. In 
both circumstances, T reg cell inhibition by means of OX40 
triggering reverts the tolerant state and allows eff  ective tumor 
elimination by host immune cells. 
  The obvious prerequisite for intratumor administration 
of OX40-agonistic mAb is the expression of OX40 on the 
surface of target cells. By fl  ow cytometry, we showed that 
almost all of the CD4  +   CD25  +   T cells in tumor beds highly 
after tumor challenge. Indeed, PC61 persistence in circula-
tion for up to 13 d has been previously reported (  45  ). 
  The three phases of immunoediting (i.e., elimination, equi-
librium, and escape) result from the cross talk between tumor 
and host immune cells (  46  ). In mice that have had natural T reg 
cells systemically inactivated by anti-OX40 mAb, the tumor  –
  host interaction stops at the fi  rst phase of immunoediting be-
cause the development of an optimal endogenous response 
quickly eliminates tumor cells that are not allowed to establish 
some equilibrium with the immune cells. This observation sug-
gests that in naive mice natural T reg cells impede the immune 
activation necessary for primary elimination of tumor cells. 
  Once tumor cell elimination by host cells has failed, the 
equilibrium and escape phases soon occur. Growing tumors 
evade possible immune cell attacks by several strategies, 
including the increase of T reg cell number and selective 
recruitment of T reg cells into the tumor bed. The pool 
of tumor-associated T reg cells derives from the expansion of 
naturally arising T reg cells and from peripheral conversion of 
    Figure 9.         T reg cell inhibition and effector T cell co-stimulation are required for OX86-induced tumor rejection.   Rag1-KO C57BL/6 mice were 
injected i.v. with WT CD8  +   T cells in addition to a mixture of CD4  +   T cells comprising 1:10 mixed combinations of CD4  +   CD25 +   (Treg) and CD4  +   CD25       (Teff) 
cells, respectively, purifi  ed from spleens of WT CD45.1 or OX40-KO CD45.2 mice. After 4 wk, mice were injected s.c. with 5   ×   10  5   MCA203 tumor cells and 
treated with intratumor injection of OX86 when tumors reached 3  –  4 mm in size. Similarly treated WT and OX40-KO mice were used as controls. Tumor 
growth is reported in cubic millimeters; each line represents a single tumor. The number of mice rejecting tumor out the total number of treated mice is 
indicated. When mice were killed, draining lymph nodes were collected and stained to check that the donor T cell mixtures were in the right proportions. 
A representative plot showing Foxp3 versus OX40 expression (percentages) on gated CD4  +   T cells is reported for every experimental group. *, P   <   0.05.     JEM VOL. 205, April 14, 2008 
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express OX40. Among them, the vast majority consists of 
Foxp3  +   T reg cells. Notably, the expression level of OX40 
by tumor-infi  ltrating T reg cells was signifi  cantly higher than 
splenic T reg cells. The reason for this diff  erence is still un-
known. Nevertheless, OX40 up-regulation might result from 
T reg cell activation, behaving similarly to other activation 
markers up-regulated by tumor-infi  ltrating T reg cells (  4  ). 
A similar expression pattern can be suggested for OX40 ex-
pression on human T reg cells, which, being OX40 negative 
in the circulation, acquire OX40 expression at eff  ector sites 
at infl  amed joints in rheumatoid arthritis (  48  ) and likely at the 
tumor site in cancer patients. The possibility of OX40 up-
regulation by tumor-infi  ltrating human T reg cells implies 
that anti-OX40 mAb may preferentially trigger tumor-asso-
ciated T reg cells with less eff  ect on the systemic T reg cell 
pool that is necessary for self-tolerance control. 
  OX40L is transiently expressed on the surface of activated 
B cells and of DCs at late phases of maturation to convey a 
late co-stimulatory signal to activated T cells. In addition, ac-
tivated eff  ector T cells can up-regulate OX40L at the very 
late phases of activation (  49, 50  ). However, those conditions 
are unlikely in the tumor microenvironment, characterized 
by profound immunosuppression. Accordingly, we could not 
detect any OX40L-positive cells in the tumor mass. This ob-
servation suggests that in the tumor microenvironment, CD4  +   
CD25  +   T cells cannot receive any triggering signal on OX40 
unless the agonist mAb is given. 
  We compared the effi   cacy of intratumor administration 
of OX40-triggering mAb with that of anti-CD25 (PC61) 
and anti-CD4 (GK1.5) depleting mAb. Intratumor deple-
tion of CD25-positive T cells does not result in any thera-
peutic eff  ect, whereas few rejections can be obtained by 
depleting CD4  +   T lymphocytes. Most likely, recruitment 
mechanisms may promptly reestablish T reg cells within 
the tumor beds after their local depletion. Moreover, anti-
CD25 can concurrently deplete CD25  +  -activated eff  ectors, 
    Figure 10.         OX40-induced T reg cell inhibition prevents the conversion of effector T cells into T reg cells.   Effect of intratumor agonistic OX40 
mAb on adoptively transferred CD4  +   T lymphocytes. To test whether anti-OX40 mAb given intratumorally can directly affect lymphocytes circulating in 
nearby lymph nodes, 3.5   ×   10  6   CD4 +   CD25       OTII cells were injected i.v. in C57BL/6 WT or OX40-KO mice that were either tumor free or bearing MCA203 
tumors. After 2 d, OVA protein was injected within the tumor (or s.c. in the fl  ank of tumor-free controls) together with OX86 or control rat IgG. 2 d later, 
draining lymph nodes were collected and analyzed by fl  ow cytometry. Because tumor bearers can be considered a tolerogenic environment, we tested 
whether the adoptively transferred OTII cells gain Foxp3 in the course of tolerogenic activation and whether intratumor OX86 can prevent such an event. 
(A) The percentage of clonotypic OTII cells expressing Foxp3 in all tested conditions (representative dot plots are shown; top). (B) In OX40-KO hosts, 
intratumor-injected OX86 failed to prevent the gaining of Foxp3 by donor lymphocytes despite their expression of OX40 (percentages are indicated). 
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CCR7-KO mice (  52  ). Extranodal priming and compensatory 
mechanisms could overcome CCR7 defi  ciency in these sys-
tems. Accordingly, we detected CD4  +   CD25  +   OX40  +   Foxp3        
T cells among TILs of CCR7-KO tumor bearers. Even if 
some delayed priming might occur, the rapid tumor growth 
renders the newly activated T cells useless because tumor bur-
den becomes too large and its fate irreversible. Interestingly, 
CD4  +   TILs of CCR7-KO mice contain a higher proportion 
of eff  ector T versus T reg cells compared with WT tumors. 
This is compatible with the accumulation at the tumor site 
of eff  ector/memory T cells that require CCR7 expression to 
leave peripheral tissues and enter lymphatics (  53, 54  ). 
  The possibility that, upon intratumor T reg cell inhibi-
tion, DCs are reprogrammed toward an immunogenic rather 
than tolerogenic pathway fi  nds confi  rmation by showing their 
enhanced migration to the draining lymph node. 24 h after 
the intratumor injection of fl  uorescent microbeads, the num-
ber of CD11c  +   cells that have engulfed fl  uorescent particles at 
the tumor site and have migrated to the draining lymph node 
is greatly increased if anti-OX40 mAb was coinjected with 
the beads. Such improved migration results in a signifi  cant 
increase of tumor-specifi  c CTLs detectable in the draining 
lymph node 5 d after intratumor OX86 treatment. 
  Although several papers indicate T reg cell inhibition of 
T cells priming within the tumor-draining lymph node (  55, 56  ), 
our data indicate that such inhibition can take place begin-
ning from the tumor site. Rather, TIDCs unleashed from lo-
cal suppression mature, thus becoming resistant to any further 
T reg cell suppression at the draining lymph node (  57  ). Alter-
natively, a small amount of intratumor-injected mAb may 
reach the draining lymph node via lymphatics, thus restoring 
the nodal priming activity. 
  Accordingly, intratumor injection of OVA protein as an 
exogenous antigen leads to abortive T cell activation unless 
anti-OX40 mAb is coadministered. A similar pattern of unre-
sponsiveness has been described in A20-HA  –  bearing mice 
(  58  ). In both models, transfer of clonotypic CD4  +   CD25        T 
cells shows that tumor induces the tolerogenic activation of 
transferred T cells and their conversion into Foxp3  +   regulatory 
cells. Injection of OX86 prevents their gaining of Foxp3. 
  In addition, it has been recently shown that direct co-stim-
ulation through OX40 during the priming impedes the acqui-
sition of a regulatory phenotype (  40, 41  ). Using an adoptive 
transfer experiment in OX40-KO recipients, we confi  rm this 
fi  nding in a tumor setting and provide new evidence that ago-
nistic OX40 mAb given intratumorally mainly acts on envi-
ronmental, nearby lymphocytes rather than directly on donor 
clonotypic T cells, which become unable to gain the Foxp3 
marker. Therefore, in this model, it is conceivable that preex-
isting tumor-infi  ltrating CD4  +   T reg and eff  ector T cells, be-
ing the prime targets of anti-OX40 mAb, can indirectly modify 
the tumor microenvironment favoring the immunogenic 
rather than tolerogenic activation of exogenous OTII cells. 
  Recent observations have raised a concern about the risk of 
generalized autoimmune disease in case of excessive co-stimu-
lation (  59  ). Many features of OX40 triggering sustain its safety. 
thus abolishing any potential benefi  t derived from T reg 
cell elimination. 
  Anti-CD4 mAb, although sparing CD8  +   T cells, elimi-
nates both T reg and T helper cells and is poorly eff  ective in 
tumor rejection. In the tumor model that we have extensively 
examined, the vast majority of tumor-infi  ltrating T lympho-
cytes were CD4  +   T cells, whereas the few CD8  +   T cells ex-
pressed low levels of CD25 and OX40 (unpublished data). 
It is conceivable that in this setting, the few CD8  +   T cells are 
unable to induce tumor rejection and that new CD8  +   T cells 
cannot be generated because of the concurrent elimination of 
T helper cells by the anti-CD4 mAb. Other more immuno-
genic tumors, such as the Ag104 model, can be rejected by 
the sole intratumor CD4 depletion, which rescues the endog-
enous robust CD8 concomitant immunity otherwise inhib-
ited by T reg cells (  35  ). 
  The minority of Foxp3        CD4  +   CD25  +   OX40  +   tumor-
infi  ltrating activated T cells can also be triggered by anti-OX40 
mAb in vivo. Notably, this stimulation is thought to be bene-
fi  cial to the overall antitumor immunity by actively boosting 
eff  ector cells. Indeed, tumor-infi  ltrating eff  ector cells are sup-
posed to be in a tolerant state that can be actively reversed by 
OX40 co-stimulation (  19  ). By reconstituting Rag1-KO mice 
with OX40-competent T reg cells and OX40-defi  cient eff  ec-
tors, we demonstrated not only that eff  ector co-stimulation 
occurs upon intratumor OX40 triggering, but also that such a 
mechanism is necessary to achieve eff  ective tumor therapy. 
On the other hand, T reg cell inhibition remains a crucial step 
through which OX40 triggering mediates tumor rejection, 
because mice bearing OX40-suffi   cient  eff   ector T cells but 
OX40-defi   cient T reg cells also fail to reject tumor upon 
OX86 treatment. We can conclude that although OX40 trig-
gering induces opposite eff  ects on T reg and eff  ector T cells 
(i.e., inhibition and stimulation), respectively, both eff  ects 
concur with the same outcome in terms of tumor rejection. 
  Notably, regardless of the composition of the CD4 mix-
ture, the coinjected OX40-competent CD8  +   T cells were 
not suffi   cient to achieve tumor rejection. In other words, the 
sole tolerance reversal of preexisting CD8  +   T cells fails to al-
low immune response unless the CD4  +   help is boosted and 
the T reg cell suppression is inhibited. Similar results have 
been obtained by Song et al. (  51  ), who demonstrated that the 
sole CD8 boost through OX40 is ineff  ective against tumor 
unless paired to OX40-mediated CD4  +   T cell activation. 
  For T cell priming, TIDCs should reach the draining 
lymph node. CCR7-null DCs cannot migrate to lymph nodes 
and CCR7-KO mice have severe structural and functional 
alterations in lymphoid organs (  38  ). Therefore, in CCR7-KO 
mice, a cross talk between tumor and lymph node cannot be 
established. In these mice, the anti-OX40 mAb treatment 
completely loses any antitumor effi   cacy. The intrinsic bias of 
using CCR7-KO mice in these experiments is the impair-
ment of T cell migration to lymph nodes (  38  ). However, this 
initial fi  nding is challenged by the observation that priming 
for delayed-type hypersensitivity reactions and OVA-specifi  c 
proliferation is still possible, although with some delay, in JEM VOL. 205, April 14, 2008 
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selection with anti-CD4 MACS microbeads. CD4  +   TILs were shown to 
mainly consist of CD25  +   Foxp3  +   T cells. 
  Antibodies and fl   ow cytometric analysis.     PE-conjugated anti-CD11c 
(clone HL3), PE-conjugated anti-V    5.1/5.2 (clone MR9-4), FITC-conju-
gated anti-CD44 (clone IM7), and streptavidin-Cy5 were all purchased from 
BD Biosciences. Purifi  ed, biotin-conjugated, or PE-conjugated anti-OX40 
(clone OX86); APC-conjugated anti-Foxp3 (clone FJK-16S); PE-Cy7  –  conju-
gated anti-CD4 (clone L3T4); and FITC-conjugated anti-CD25 (clone 7D4) 
were purchased from e-Bioscience. Alexa Fluor 647  –  conjugated anti-CD8 
(clone 5H10) was purchased from Caltag. PE-conjugated H-2L  d   tetramer to 
peptide SPSYVYHQF (MuLV env gp70 423  –  431) and PE-conjugated H-2L  d   
tetramer to peptide TPHPARIGL (  Escherichia coli       -galactosidase 876  –  884) 
were purchased from Proimmune. Antibodies were used at 5   μ  g/ml, and sur-
face staining was performed in FACS buff  er (10% FCS in PBS) on ice for 
45 min. Intracellular staining of Foxp3 (clone FJK-16S) was performed on pu-
rifi  ed CD4  +   CD25  +   cells, according to the manufacturer  ’  s instructions (e-Bio-
science). Flow cytometry data were acquired on a FACSCalibur (Becton 
Dickinson) and analyzed with FlowJo software (version 8.4.5; Tree Star Inc.). 
  In vitro suppression assay.     For in vitro assays, purifi  ed CD4  +   CD25        cells 
were labeled by incubation with 5   μ  M CFSE (Invitrogen) in PBS containing 
5% FBS for 15 min at 37  °  C. Cells were washed twice with PBS and set up 
in a proliferation assay. To test T reg cell suppressive activity, 5   ×   10  4   CD4  +   
CD25        cells were cultured with 5   ×   10  4   accessory cells (consisting in the 
whole spleen irradiated with 30 Gy) with or without T reg cells for 72 h in 
complete medium containing RPMI 1640 (Sigma-Aldrich) supplemented 
with 5% FCS, 2 mM   l-  glutamine, 200 U penicillin, and 200 mg/ml strepto-
mycin (Sigma-Aldrich). For stimulation, 1   μ  g/ml of purifi  ed anti-CD3 
(e-Bioscience) was added. Where indicated in the fi  gures, T reg cells were 
preincubated at a concentration of 6   ×   10  6  /ml with 30   μ  g/ml of purifi  ed 
anti-OX40 mAb (clone OX86; e-Bioscience). Every condition was assayed 
in triplicate and analyzed after 72 h by fl  ow cytometry. 
  In vivo DC migration.     Mice bearing CT26 tumors were intratumorally 
injected with the indicated treatment plus 2   ×   10  7   FITC-conjugated latex 
particles of 1   μ  m in diameter (Polysciences). After 24 h, mice were killed and 
draining lymph nodes were collected, teased, and incubated for 30 min in 
400 U/ml collagenase D solution. Cells were stained for CD11c expression, 
and 10  6   events per lymph node were acquired by fl  ow cytometry. The total 
number of double-positive PE-CD11c/FITC bead events was calculated for 
each lymph node. 
  Reconstitution of Rag1-KO mice.     CD4  +   CD25        and CD4  +   CD25  +   T 
cells were purifi  ed from the spleens of either WT CD45.1 or OX40-KO 
CD45.2 mice on a C57BL/6 background. CD8  +   T cells were obtained from 
WT mice. Purity of the obtained populations was   >  90%, as assessed by fl  ow 
cytometry. Cells were mixed at diff  erent combinations and injected i.v. into 
Rag1-KO mice at 4 wk of age. Every mouse received the following amount of 
cells: 10   ×   10  6   CD4  +   CD25        cells, 10  6   CD4  +   CD25  +   cells, and 7   ×   10  6   CD8  +   
cells, to reconstitute a physiological-like T cell compartment into recipients. 
After 4 wk, mice were injected s.c. with 5   ×   10  5   MCA203 syngenic tumor 
cells. At the size of 3  –  4 mm, intratumor injection with 100   μ  g anti-OX40 was 
performed in two doses within a 2-d interval. Tumor growth was monitored 
every 3 d. When mice were killed, lymph nodes were collected and stained 
with PE-Cy7 anti-CD4, PE  –  anti-OX40, allophycocyanin  –  anti-Foxp3, and 
FITC  –  anti-CD8 or FITC  –  anti-CD45.2 to check for correct reconstitution. 
  Adoptive transfer of OTII clonotypic T cells.     CD4  +   CD25        T cells 
were purifi  ed from the spleens of OTII TCR transgenic mice. The purity of 
the obtained population was   >  90%, as assessed by fl  ow cytometry. C57BL/6 
WT or OX40-KO mice, tumor free or bearing tumors of 3  –  4 mm in diam-
eter, received 3.5   ×   10  6   OTII TCR-transgenic cells by tail vein injection. 
After 2 d, mice were immunized with 10   μ  g of OVA protein (Sigma-
Aldrich) without any adjuvant. The antigen was injected within the tumor 
in association to the anti-OX40 mAb or the control rat IgG. Tumor-free 
Eff  ector cells, only at late phases of activation, express OX40 
and can receive co-stimulation (  21  ). Moreover, T reg cells ex-
press OX40 constitutively in the periphery (at least in mice) 
and up-regulate this marker within the tumor; thus, the intra-
tumor route of treatment may preserve systemic tolerance. 
Mice that rejected the tumor because of OX40 treatment re-
mained perfectly healthy for a 6-mo followup without show-
ing any macroscopic sign of autoimmunity. 
  Several attempts have been made to exploit T reg cell 
neutralization as an adjuvant strategy for immunotherapy. 
Although encouraging results emerge from mouse studies, 
CD25-directed T reg cell depletion in cancer patients has not 
provided satisfactory outcomes. The prevalent failure of such 
an approach may be attributed to the concurrent depletion of 
activated eff  ectors, the possibility of triggering IL-2 receptor 
on T reg cells for activation rather than depletion, and the 
prompt replenishment of the T reg cell pool by peripheral 
conversion (  60  ). We propose T reg cell inactivation, by 
means of OX40 triggering, as a suitable alternative in cancer 
immunotherapy. Indeed, breaking the barrier of dominant 
tolerance appears to be the sine qua non for eff  ective immuno-
therapy in cancer patients. 
  MATERIALS AND METHODS 
  Mice and treatments.     BALB/c, C57BL/6, Rag1-KO, and OTII mice 
were purchased from Charles River Laboratories. CCR7-KO and OX40-
KO mice were provided by M. Lipp (Max-Delbruck-Center, Berlin, Germany) 
and N. Killen (University of California, San Francisco, San Francisco, CA), 
respectively. All mice were maintained under pathogen-free conditions in 
our animal facility and used at 8 wk of age. CT26 is a carcinogen-induced, 
undiff  erentiated colon carcinoma cell line; N2C is a primary mammary car-
cinoma cell line derived from female BALB-neuT mice; and TSA is a cell 
line derived from a spontaneous breast adenocarcinoma (all on BALB/c 
background). MCA203 is a C57BL/6-derived fi  brosarcoma induced by 
3-methylcholanthrene. Tumor cells were cultured in DMEM (Invitrogen) 
supplemented with 10% FCS (BioWhittaker). 5   ×   10  4   CT26 cells, 2   ×   10  5   
N2C cells, 5   ×   10  4   TSA cells, or 5   ×   10  5   MCA203 cells were inoculated s.c. 
in the fl  ank of naive mice. Tumor growth was monitored twice per week 
and recorded as longest diameter   ×   (shortest diameter)  2   (in cubic millimeters). 
In vivo systemic administration of anti-CD25 mAb (clone PC61; hybridoma 
provided by V. Bronte, University of Padua, Padua, Italy), anti-OX40 mAb 
(clone OX86; European Collection of Cell Cultures), or anti-CD8 mAb 
(clone 2.43; American Type Culture Collection) was performed using a 
daily i.p. injection of 500   μ  g of ascite for two consecutive days. Purifi  ed anti-
OX40 mAb, anti-CD25 mAb, and anti-CD4 mAb (clone GK1.5; American 
Type Culture Collection) were injected within the tumor using two daily 
injections of 50   μ  g within a 2-d interval. Animal experiments were autho-
rized by the Fondazione IRCCS Istituto Nazionale dei Tumori Ethical 
Committee for animal use. 
  Purifi  cation of CD4  +   CD25  +   and CD4  +   CD25         subsets.     Total spleno-
cytes from tumor-free mice were fi  rst enriched for T lymphocytes by passing 
the whole spleen on nylon wool columns (Kisker). CD8  +   cells were re-
moved using anti-CD8 microbeads (MACS; Miltenyi Biotec). CD4  +   CD25  +   
cells were then separated from CD4  +   CD25        cells using the CD25  +   T cell 
isolation kit (Miltenyi Biotec), according to manufacturer  ’  s instruction. Flow 
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